India is set to launch its first indigenously developed Quadrivalent Human Papillomavirus Vaccine (qHPV) against Cervical cancer with the help of the Serum Institute of India (SII) and the Department of Biotechnology (DBT) on 1st September 2022. The vaccine for Cervical cancer “CERVAVAC”, will be launched by Union Minister of State Science and Technology Jitendra Singh. The vaccine is likely to cost around 200-400 per dose.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
As per the government data, cervical cancer ranks number 2 for most prevalent cancer in India and also accounts for one-fourth of the world’s cervical cancer deaths. Approximately 1.25 lakhs women are diagnosed with Cervical cancer and over 75 thousand females die from the disease in India. The Union government plans to target the age of 9-14 years of girls for vaccination against cervical cancer. Before the rollout of the vaccine, a sensitization program will be organized by the government to educate parents and school authorities. The government also said that CERVAVAC is an outcome of the partnership of DBT and BIRAC with the Bill and Melinda Gates Foundation.
Mobile Phones are a very important part of our daily life. From calling and messaging…
Mongolian parliament has appointed the Uchral Nyam-Osor as the country' new Prime Minister. With this…
To boost export potential of Indian textile industries Ministry of Textiles has extended the RoSCTL…
From the April 1st fuel stations across the country are now supplying that petrol which…
The Ministry of Education has granted the 'deemed to be university’ status to National Council…
India's Gaganyaan Mission have begun the unique experiment which is called Mission Mitra in the…